维生素 D 用于 休止期脱发
F基于32项研究(1项荟萃分析、1项RCT),共17,842名参与者。各研究结果不一。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Dvitamin\u002Dd\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
F
结论
Despite frequent associations between low vitamin D and telogen effluvium, research does not clearly support vitamin D supplementation as an effective approach for this type of hair shedding.
- Lower vitamin D levels are common in telogen effluvium patients but may not be the cause
- No well-designed RCTs demonstrate that supplementation resolves telogen effluvium
- Post-COVID hair loss studies show inconsistent findings regarding vitamin D
- Correcting a deficiency is reasonable, but vitamin D alone is unlikely to resolve hair shedding
Key Study Findings
retrospective observational
n=113
Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases.
Dose: None
vs: Placebo
效果: None
None
narrative review
Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions.
Dose: None
vs: Placebo
效果: None
None
Review
Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients.
Dose: None
vs: Placebo
效果: None
None
Meta-analysis
Vitamin D deficiency in non-scarring and scarring alopecias: a systematic review and meta-analysis.
Dose: None
vs: Placebo
效果: OR=2.84 (AA vs controls), OR=5.24 (FPHL vs controls)
p<0.01
case-control study
n=180
A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, …
Dose: not applicable
vs: Placebo
效果: None
None
meta_analysis
n=10670
Serum 25 hydroxyvitamin D in non-scarring alopecia: A systematic review and meta-analysis.
Dose: not applicable (observational meta-analysis)
vs: Placebo
效果: WMD -7.29 ng/mL (95% CI -9.21, -5.38); OR for vitamin D deficiency 3.11 (95% CI 2.29, 4.22)
not explicitly stated; CI does
Key Statistics
34
研究数量
17842
受试者
↔
Mixed
F
等级
Referenced Papers
Nutrients
2025
2 次引用
Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases.
Other
International journal of …
2025
Journal of drugs …
2025
Journal of cosmetic …
2024
7 次引用
Serum 25 hydroxyvitamin D in non-scarring alopecia: A systematic review and meta-analysis.
Meta-Analysis
Journal of cosmetic …
2024
7 次引用
Archives of dermatological …
2024
5 次引用
Vitamin D deficiency in non-scarring and scarring alopecias: a systematic review and meta-analysis.
Systematic Review
Frontiers in nutrition
2024
4 次引用
Dermatology practical & …
2024
Pediatric dermatology
2023
9 次引用
Dermatology practical & …
2023
4 次引用
Archives of dermatological …
2023
3 次引用
Oral Vitamin D Treatment in Patients with Telogen Effluvium: Clinical and Dermoscopic Evaluation.
Other
International journal of …
2023
1 次引用
Journal of cosmetic …
2022
22 次引用
Human nutrition & …
2022
9 次引用
Turkish journal of …
2022
8 次引用
Journal of the …
2022
6 次引用
Dermatology practical & …
2022
6 次引用
JAAD international
2022
6 次引用
Journal of dermatological …
2021
51 次引用
Journal of cosmetic …
2021
44 次引用
Anais brasileiros de …
2021
26 次引用
Cureus
2021
20 次引用
Journal of nutritional …
2021
12 次引用
Dermatology online journal
2021
3 次引用
International journal of …
2020
18 次引用
Experimental dermatology
2020
10 次引用
NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.
Observational
Journal of cosmetic …
2019
25 次引用
Clinical, cosmetic and …
2019
7 次引用
International journal of …
2017
61 次引用
Journal of drugs …
2016
56 次引用
International journal of …
2016
28 次引用
Journal of cutaneous …
2014
10 次引用
Skin pharmacology and …
2013
127 次引用
The British journal …
2005
40 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 600-800 IU/day
- deficiency:
- 1,000-5,000 IU/day
上限: 4,000 IU/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Neutral | 113 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| not applicable | -- | Mixed | 180 |
| not applicable (observational meta-analysis) | -- | Negative | 10670 |
| None | -- | Mixed | 100 |
| None | -- | Neutral | 120 |
最佳服用时间: With a fat-containing meal for optimal absorption
Safety & Side Effects
已报告的副作用
- ⚠ Hypercalcemia at very high doses (nausea, vomiting, weakness)
- ⚠ Kidney stones with excessive long-term use
- ⚠ Constipation
- ⚠ Metallic taste
已知相互作用
- ● Thiazide diuretics (may increase risk of hypercalcemia)
- ● Corticosteroids (reduce vitamin D absorption and metabolism)
- ● Orlistat and cholestyramine (reduce fat-soluble vitamin absorption)
可耐受最高摄入量: 4,000 IU/day
在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does 维生素 D help with 休止期脱发?
Based on 34 studies with 17,842 participants, there is insufficient evidence at this time that 维生素 D may support 休止期脱发 management. Our evidence grade is F (Evidence Against).
How much 维生素 D should I take for 休止期脱发?
Studies have used various dosages. A commonly studied range is 600-800 IU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 维生素 D?
Reported side effects may include Hypercalcemia at very high doses (nausea, vomiting, weakness), Kidney stones with excessive long-term use, Constipation, Metallic taste. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 维生素 D and 休止期脱发?
We rate the evidence as Grade F (Evidence Against). This rating is based on 34 peer-reviewed studies with 17,842 total participants. The overall direction of effect is mixed.
Related Evidence
其他成分用于 休止期脱发
FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。